New and Improved Goodwin Biotechnology Upstream Manufacturing Department Assets

As the 2016 Spring Season passaged into the summer, a new culture was seeded Upstream Manufacturing at Goodwin Biotechnology, as a 200L Single Use Bioreactor (SUB) and Alternating Tangential Flow (ATF) Perfusion System was added to our Upstream Operational capacity.


The Upstream Manufacturing Team from Goodwin and representatives from Repligen Corporation and GE Healthcare huddled to flip the switch and start the operations and training on the new Systems. Working together the system manufacturers provided familiarity and crossover with the Large Scale Stirred Tank Reactor (STR) systems that are currently in house.

Highly Specialized Fill and Finish

For more than 20 years, Goodwin Biotechnology has developed into a uniquely qualified CDMO that provides a Single Source Solution™ for  clients by offering cell line development,  exploratory proof-of-concept projects through Process Development and cGMP manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and biologic drug conjugates including antibody drug conjugates (ADCs) for small startup ventures to large, multi-national companies as well as government agencies and medical institutions for early and late stage clinical trials. As part of their integrated services offerings, Goodwin Biotechnology operates an ISO5 cGMP filling suite that can accommodate liquid filling of a wide range of configurations to meet specific and unique client requirements.

Downstream Purification Expertise is Critical

Process Development

Goodwin Biotechnology's downstream process development group has well over 50 years of experience in developing and refining purification processes for recombinant proteins. With an extensive background in the purification of proteins from mammalian, as well as plant and animal transgenic systems, Goodwin Biotechnology can quickly develop a purification process for clients that will maximize yields for the target molecule, meet required purity levels, and be compliant with the regulatory requirements for product's development status.

ENHANCING ADCs TO TARGET DISEASED CELLS AND DELIVER PAYLOADS

Insulin-like growth factor or IGF is a natural growth hormone, which plays an important role in normal growth and development. Six soluble insulin-like growth factor-binding proteins or IGFBPs and IGFBP proteases regulate its actions. These binding proteins bind to Insulin-like growth factor with high affinity and specificity[1].

An Overview of the General Cell Culture Work at Goodwin Biotechnology

Goodwin Biotechnology is a leading biological Contract Manufacturing Organization (CMO) that offers a full range of mammalian cell culture services ranging from the creation of up and downstream processes sufficient for the manufacturing of proof of concept, toxicology product material and processes for licensed manufacturing. 

Goodwin Biotechnology-- Your Single Source Solution™ for Cytotoxic ADCs

Together with our collaborative partner, Coldstream Labs, GoodwinBiotechnology has the experience, expertise, and capability to develop and manufacture highly potent CADCs from proof of concept through to non-clinical and clinical use, late stage as well as commercial manufacturing.

Goodwin Biotechnology is a full-service, customer-focused and integrated contract services provider with a pioneering focus on the development and manufacturing of Cytotoxic Antibody Drug Conjugates (CADCs) from cell line development or exploratory proof-of-concept through process development, scale up,  and cGMP manufacturing. 

Goodwin Biotechnology Global Customer Value Leadership Award for Mammalian Biologics Contract Manufacturing

Frost & Sullivan Presents

Goodwin Biotechnology with the Global Customer Value Leadership Award for Mammalian Biologics Contract Manufacturing

Goodwin Biotechnology pioneered best-in-class practices for the development of complex Biopharmaceuticals and Antibody Drug Conjugates (ADCs)

LONDON — September 2, 2014 — Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology’s reputation as one of the most trusted providers of mammalian contract manufacturing and development services has been built on more than 20 years of experience in the bioprocess development and cGMP manufacturing of mammalian cell culture-derived monoclonal antibodies (mAbs), vaccines, and recombinant proteins, and more than 10 years pioneering the field of bioconjugation.